Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Meta-analysis and Meta-regression Applicability
Author(s): Alberto Cordero , Carlos G Santos-Gallego , Armando Oterino , et al Added: 3 months ago

CV Disease in Special Populations
ESC 25: The CARUSO Trial
Author(s): Tiziana Claudia Aranzulla Added: 4 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more

Intervention

Prevention & Chronic Conditions
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 9 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
EASD 23: Efinopegdutide in NAFLD & T2D patients
Author(s): Samuel S Engel Added: 2 years ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Oxidative Stress Genes Predict Survival in STEMI
Author(s): Shuo-wen Sun , Xing-jie Wang , Ruo-chen Yan , et al Added: 9 months ago

MI/ACS

Prevention & Chronic Conditions
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 7 months ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
CardioNerds @AHA23: KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension
Author(s): George L Bakris , Sukriti Banthiya Added: 2 years ago
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035).This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients… View more

Prevention & Chronic Conditions
Robert M Wachter
Research Area(s) / Expertise:
Robert M Wachter is Professor and Chair of the Department of Medicine at UCSF and a leading figure in hospital medicine, having coined the term “hospitalist” in 1996. He is the author of six books, including the New York Times bestseller The Digital Doctor, with his latest, A Giant Leap: How AI is Transforming Healthcare and What That Means for Our Future, forthcoming from Portfolio/Penguin in… View more
AHA 25: The PFA-SHAM Study
Author(s): Vivek Reddy Added: 2 months ago
AHA 2025 - Dr Vivek Y Reddy (Icahn School of Medicine at Mount Sinai, New York, US) joins us to share findings from the PFA-SHAM study (NCT05717725) investigating pulsed field ablation (PFA) versus sham ablation to treat AF. Patients enrolled in the study underwent an electrophysiology study to ensure they had no concealed AV bypass tract or supraventricular tachycardia, and patients were then… View more

Electrophysiology & Arrhythmia
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure